Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 39,648 | 36,600 | 31,598 | 20,760 | 27,142 |
| TOTAL | $41,820 | $37,998 | $33,334 | $22,794 | $29,465 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 7 | 40 | 71 | 103 | 135 |
| TOTAL | $7 | $40 | $71 | $103 | $135 |
| Total Assets | $41,827 | $38,038 | $33,405 | $22,897 | $29,600 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,805 | 1,917 | 924 | 382 | 1,292 |
| Accrued Expenses | 7,163 | 6,382 | 5,065 | 4,281 | 4,042 |
| TOTAL | $9,033 | $8,299 | $6,054 | $4,663 | $5,399 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 30,178 | 20,490 | 10,235 | 0 | 8 |
| TOTAL | $30,178 | $20,490 | $10,235 | $N/A | $8 |
| Total Liabilities | $39,211 | $28,789 | $16,289 | $4,663 | $5,407 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 59,358 | 59,341 | 59,275 | 58,095 | 57,156 |
| Common Shares | 59 | 59 | 59 | 56 | 56 |
| Retained earnings | -270,694 | -263,407 | -254,850 | -246,336 | -239,996 |
| Other shareholders' equity | 2,250 | 2,250 | 2,250 | 2,250 | 2,250 |
| TOTAL | $2,616 | $9,249 | $17,116 | $18,234 | $24,193 |
| Total Liabilities And Equity | $41,827 | $38,038 | $33,405 | $22,897 | $29,600 |